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Abstract
A nanoemulsion drug delivery system was developed to increase the oral bioavailability of
mebudipine as a calcium channel blocker with very low bioavailability profile. The impact of
nano-formulation on the pharmacokinetic parameters of mebudipine in rats was investigated.
Nanoemulsion formulations containing ethyl oleate, Tween 80, Span 80, polyethylene glycol
400, ethanol and deionized water were prepared using probe sonicator. The optimum
formulation was evaluated for physicochemical properties, such as particle size, morphology
and stability. The particle size of optimum formulation was 22.8 ± 4.0 nm. Based on the results
of this study, the relative bioavailability of mebudipine nanoemulsion was enhanced by about
2.6-, 2.0- and 1.9-fold, respectively, compared with suspension, ethyl oleate solution and
micellar solution. In conclusion, nanoemulsion is an interesting option for the delivery of poorly
water soluble molecules, such as mebudipine.
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Introduction
Nanoemulsions are isotropic mixture of oil, surfactant and
water with droplet diameter approximately in the range of
10–100 nm (Azeem et al., 2009). They are thermodynamically
stable and have various advantages as drug carriers, e.g. rapid
onset of action, ease of preparation and scale up, drug
protection against hydrolysis and oxidation, improvement of
drug efficacy and minimizing total dose required as well as
the side effects (Debnath et al., 2011).
Mebudipine [(±)-t-butyl, methyl-1,4-dihydro-2,6-dimethy-
4-(3-nitrophenyl)-3,5-pyridine 3 dicarboxylate] (MB) is a new
1,4-dihydropyridine derivative of calcium channel blockers
(CCBs) (Mahmoudian et al., 1997). Previous in vivo studies
have shown pharmacological properties of MB comparable to
prototype 1,4-dihydropyridine, nifedipine (Faizi et al., 2003).
Changes in chemical structure of this molecule (i.e. substi-
tution of methyl ester in nifedipine with t-butyl ester) have
reduced the conversion rate of parent 1,4-dihydropyridine to
an inactive metabolite (Bohlooli et al., 2004b). Thus, longer
biological half-life (T1/2) and time to reach maximum effect
(Tmax) is observed in MB (Bohlooli et al., 2004a). However,
oral bioavailability of the drug is very low (approximately
1–2%), similar to many other dihydropyridines, such
as nimodipine (Kale & Patravale, 2008), lacidipine
(Gannu et al., 2010) and nitrendipine (Choi et al., 2003).
Such a poor bioavailability is attributed to low water
solubility, high first-pass metabolism by cytochrome P450
and P. glycoprotein mediated efflux (Hecq et al., 2006).
In recent years, nanoemulsion systems have received
increasing attention as an appropriate carrier system for
insoluble active compounds to increase their bioavailability
and modify drug release characteristics (Han et al., 2009;
Kotta et al., 2013; Sharma et al., 2014; Verma et al., 2014).
For instance, improved oral bioavailability of amlodipine
(Chhabra et al., 2011) and felodipine (Veerareddy et al., 2012)
nanoemulsions in comparison with the conventional prepar-
ations has been reported.
In order to enhance bioavailability of MB, in this study, we
attempted to develop and optimize a novel nanoemulsion
formulation. Subsequently, oral bioavailability and pharma-
cokinetic parameters of MB-loaded nanoemulsion was
examined in conscious Rat.
Materials and methods
Materials
HPLC grade solvents, such as acetonitrile, methanol and
dichloromethane were obtained from Merck Chemicals
(Darmstadt, Germany). The vegetable oils were provided by
Barij Essence Co. (Kashan, Iran). Dibudipine and mebudipine
were purchased from Pars Biopharmacy Research Co.
(Tehran, Iran). Ethyl oleate, Span 80 (S80), Tween 20
(T20), Tween 80 (T80), Propylene glycol, Isopropyl
Alcohol and Polyethylene glycol (PEG 400) were obtained
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from Merck chemicals (Darmstadt, Germany). Lipoid S75
(S75) was supplied by Lipoid GmbH (Ludwigshafen,
Germany). Double distilled water was obtained through a
Milli-Q system (Millipore, Billerica, MA).
Methods
Preparation of MB nanoemulsion
In order to select the appropriate oily phase, the saturation
solubility of MB in different oils was assessed. An excess
amount of drug was added to 1 ml of vehicle in each vial and
vortexed for 10 min. Then, vials were shaken for 48 h at room
temperature to reach equilibrium. Subsequently, the suspen-
sion was centrifuged (Eppendorf, Hamburg, Germany) at
3000 rpm for 15 min and the excess insoluble MB was
removed by filtration through a 0.2-mm syringe filter
(Whatman, Dassel, Germany). The mebudipine concentration
in various components was measured via high performance
liquid chromatography (HPLC).
Hydrophilic Lipophilic Balance (HLB) system was then
used to determine the correct ratio of surfactant composition,
which is required to achieve desired stability of prepared
emulsion. Emulsification efficiency of various surfactants
was assessed based on percentage transmittance through
turbidimetric method (Elsheikh et al., 2012).
Mebudipine solubility in various co-surfactants, including
isopropyl alcohol, propylene glycol, polyethylene glycol and
ethanol was determined. The turbidimetric method was also
used to assess the relative efficacy of the selected surfactant/
co-surfactant mixture (Smix) to improve the nanoemulsifica-
tion ability of surfactants.
Construction of phase diagram
Aqueous titration method was used to draw the diagrams using
CHEMIX software (version 3.51) (Bergen, Norway). The
selected surfactant (T80 + S80) and co-surfactant (PEG
400 + ethanol) were mixed (Smix) at different weight ratios
(1:0, 1:1, 1:2, 2:1, 3:1).
Sixteen different proportions of oil:Smix (1:9, 1:8, 1:7, 1:6,
1:5, 1:4, 1:3.5, 1:3, 1:2.33, 1:2, 1:1.5, 1:1, 1:0.66, 1:0.43,
1:0.25, 1:0.11) were prepared to determine the boundaries of
different phases in the phase diagram. Slow titration with
aqueous phase was performed to each oil:Smix ratio and
samples were visually observed for any phase separation.
Transparent and easily flowable mixtures were dotted on phase
diagram as o/w nanoemulsion (Shafiq-Un-Nabi et al., 2007).
Selection of formulation
From each phase diagram, formulations containing 10–20% oil
(enough to solve a single-dose of MB, required for kinetic
studies) and minimum concentration of Smix to form a nano-
emulsion were chosen and tested for their stability as follows:
Centrifugation study: Samples were centrifuged at 5000 rpm
for 30 min. Those formulations which did not show any
creaming, cracking and phase separation were selected for
heating–cooling cycles.
Heating–cooling cycles: Samples were translocated for six
cycles of 4 C and 45 C (48 h) and their stability were
evaluated.
Freeze-thaw cycles: Three freeze-thaw cycles (48 h) were
performed for the formulations between 21 C and +25 C.
Any instability sign, such as phase separation was
investigated.
Droplet size analysis
Particle size of selected samples was determined by a photon
correlation spectroscopy (PCS) instrument (Zetasizer Nano
ZS, Malvern, UK). Prior to measurements, formulations
(50 ml) were diluted to 2 ml with double distilled water to
avoid particle interactions and additional scattering during
measurement. The dispersant viscosity was set at 0.8872cP
at 25 C.
Transmission electron microscopic analysis
Morphology of droplets was observed using transmission
electron microscopic (TEM) (Zeiss, Jena, Germany). One
drop of diluted sample (100 times) was placed on a 200-mesh
film grid and dried at room temperature. Samples were
stained with uranyl acetate and allowed to dry for 10 min
before observation with the electron microscope.
Pharmacokinetic study
Male Wistar rats (n¼ 24) weighing 250–300 g were used for
in vivo experiments. Rats were maintained under standard
laboratory conditions. Approval to carry out in vivo studies
was obtained from the Ethics committee of the Iran
University of Medical Sciences. The animals had free
access to food and water and were deprived of food overnight
before each experiment. Four different formulations contain-
ing MB, namely, nanoemulsion, micellar solution, oily
solution and suspensions were administered orally to rats
with a gavage needle at a single dose of 10 mg/kg. The
nanoemulsion had Smix (50%) and oil (10%) in water, while
the micellar solution was consisted of Smix (50%) and water
(i.e. nanoemulsion without oil). Oily solution contained ethyl
oleate (100%) and suspension contained small amount of
hydroxymethylcellulose as suspending agent and water. A
microsurgical technique was used to collect blood samples
from the right atrium through a catheter (cannula) implanted
into the right external jugular vein of adult rats (Thrivikraman
et al., 2002). Blood samples (0.5 ml) were collected from rats
and deposited into heparinized tubes (1.5 ml) at the following
time intervals: 0, 10, 20, 30, 60, 90, 120, 240 and 360 min.
Samples were immediately centrifuged at 5000 rpm for
20 min. Plasma was then separated and stored at 20 C
until used for further analyses by HPLC.
Analysis of MB concentration in plasma
Analysis was carried out using in-house developed HPLC
method (Khani & Keyhanfar, 2014). MB was extracted from
the rat plasma via liquid-liquid extraction method. A mixture
of plasma sample (200ml) and internal standard solution
(10 ml of a 4 mg/ml dibudipine) was placed in an Eppendorf
microtube and mixed for 10 s. 200 ml of NaOH (1 N) was
added and the sample was vortexed for 1 min. 2 ml of
dichloromethane was added and vortexed vigorously for
5 min to precipitate proteins. The mixture was centrifuged at
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5000 rpm at 20 C for 25 min. The organic layer was transferred
to a separate tube and dried under flowing nitrogen in a water
bath (40 C). The dried extract was reconstituted in 100 ml of
the mobile phase and, after thorough mixing, 20 ml of the
sample was injected onto the HPLC column. A Younglin
HPLC system equipped with Younglin 600 pump, UV-VIS
detector, manual injector, Autochro-2000 software (Kyounggi-
do, Korea) and a tracer excel ODS-A analytical column
(4.6 250 mm, 5 mm) was utilized. Mobile phase consisted of
methanol-water-acetonitrile (70-25-5) and pumped at a flow
rate of 1 ml/min during analysis. Wavelength used for screen-
ing was 238 nm. All HPLC grade solvents were sonicated for
10 min in bath sonicator (Starsonic 60, Liarre, Italy) before use.
Validation of the HPLC method was carried out by
calculating the accuracy and precision of method as well as
the calculation of intra-day and inter-day analytical variability
(Khani & Keyhanfar, 2014). Calibration curves were recorded
and checked for linearity. Recovery percentage of MB was
determined at three different concentrations (100, 500,
1000 ng/ml) (Keyhanfar et al., 2014).
Pharmacokinetic data analysis
Maximum concentration (Cmax) and the corresponding peak
time (Tmax) were recorded and area under the plasma
concentration–time curve up to last time (AUC0–t) was
calculated using linear trapezoidal rule. Area under the curve
calculated to infinity (AUC0–1) was then calculated via sum of
the areas obtained by the trapezoidal method (AUC0–6) and
residual area (AUC6–1). The residual area and T½ were
obtained according to following equations (Hedaya, 2012):
AUCt1 ¼ Ct=ke
T ¼ ln 2=ke
where, ke and Ct represent elimination rate constant and last
measured concentration, respectively. Percentage of relative
bioavailability (F) of MB nanoemulsion to the aqueous
suspension, oily solution and micellar solution was calculated
according to the following equation, considering the fact that
same doses were administered orally in all the formulations:
Percent relative bioavailability¼ AUC0!1product
AUC0!1reference
 
 10
Statistical analysis
Statistical analyses were carried out using SPSS software
version 14.0 (Chicago, IL). A comparison of means was made
between groups using one-way analysis of variance followed
by Tukey’s post-hoc test. The results were expressed as
mean ± S.D. and considered statistically significant at 95%
confidence (p50.05).
Results
Preparation of nanoemulsion
Selection of nanoemulsion components
Solubility tests were performed to select the appropriate oil
phase. Obtained results showed that MB exhibited highest
solubility in ethyl oleate (17.6 ± 0.3 mg/ml) in comparison
with other oils (Figure 1).
The solubility test showed that polyethylene glycol and
ethanol provided the highest solubilizing capacity of MB
(Figure 2).
The results have shown that the mixture of PEG
400 + ethanol as cosurfactant and Tween 80 + Span 80 as
surfactant can greatly enhance the transparency of the
formulation (Table 1).
Pseudo-ternary phase diagram study
Pseudo-ternary phase diagram was constructed to help in
selection of the optimum ratio of components (oil, surfactant
and co-surfactant) in nanoemulsion formulation. The dotted
area indicates the nanoemulsion region. Comparing the data
from nanoemulsions with and without MB, no change was
found in nanoemulsion region of diagrams (data not shown).
Therefore, only the phase diagrams of nanoemulsion with MB
are provided in Figure 3. From the results, a wider
nanoemulsion region with elongation toward the water-rich
apex is obtained for Figure 3(B) (i.e. 1:1 ratio).
Therefore, Smix ratio¼ 1:1 was selected to study the effect
of co-surfactant components ratio on nanoemulsion forma-
tion. It can be observed from Figure 4 that optimum ratio of
the two co-surfactants used in the preparation are A (PEG/
Etoh¼ 1:1) and B (PEG/EtOH¼ 2:1) to dissolve max-
imum amount of oil (i.e. broader nanoemulsion area).
Furthermore, the diagrams A and B represent extension
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Figure 1. Solubility of MB in various oils. Data expressed as mean ± SD
(n¼ 3).
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Figure 2. Solubility of mebudipine in various solvent. Data expressed as
mean ± SD (n¼ 3).
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towards aqueous-rich apex, which shows the ability of such
formulations to be diluted with water.
Thermodynamic stability studies
Stability tests included centrifugation study, heating–cooling
cycles and freeze-thaw cycles were carried out on selected
formulations from phase diagram A and B and the results are
given in Table 2.
Those formulations which successfully passed the stability
tests were taken for size analysis on the first day and the third
month after preparation (Table 3). From the particle size
analysis results, sample MF2 with minimal change in the
particle size was selected as optimum sample for further
investigations. Ratio of different ingredients in the sam-
ple was oil/Tween 80/Span 80/PEG 400/ethanol/water
(1:1.58:0.92:1.66:0.84:4).
TEM analysis
The particles appeared nearly spherical with particles mostly
smaller than 50 nm, a finding in agreement with the results
obtained using PCS (Figure 5).
Pharmacokinetic data analysis
Plasma concentration–time profiles of MB after oral admin-
istration of nanoemulsion, oily solution, micellar solution and
suspension have been indicated in Figure 6. The results (Table
4) show that nanoemulsion formulation can increase AUC0-1,
AUC0–6h and Cmax significantly (p50.001) compared to other
formulations but T½ and Tmax do not show any significant
change. The relative bioavailability values of MB following
oral administration of nanoemulsion compared with the
aqueous suspension, oily solution and micellar solution were
2.63, 2.01 and 1.94%, respectively. As can be observed from
Table 4, the AUC0–6h of micellar solution was also signifi-
cantly (p50.05) higher than MB suspension.
Discussion
Mebudipine has exhibited potent vasodilatory effects similar
to nifedipine with less negative chronotropic activity in rat
(Sepehr-Ara et al., 2011). However, no systematic clinical
trial has been performed on this molecule yet. This is because
of its poor water solubility and low oral bioavailability.
In this study, we decided to develop a nanoemulsion
formulation of MB to enhance its bioavailability. An attractive
aspect of O/W nanoemulsions is their ability to incorporate
hydrophobic drugs into the oily phase, thereby enhancing
their solubility (Vatsraj et al., 2014). Different oils were
examined in solubility studies and Ethyl oleate was suggested
as the best solvent for MB, thus, selected as our oily phase.
The solubility of drug in the oily phase is an important factor
in designing a formulation because drug loading in formula-
tion, ability of formulation to keep drug in solubilized form in
GI and volume of formulation for delivery of therapeutic dose
directly depend greatly on its solubility in the vehicle (Azeem
et al., 2009). Among various surfactants, non-ionic ones have
advantages, such as less toxicity, lower CMC values and
higher in vivo stability profiles. Furthermore, they are less
affected by changes in pH and ionic strength (Bali et al.,
2010). Here in, mixture of Tween 80 and Span 80 was
selected as a safe and biocompatible surfactant system that
produced a transparent and stable formulation.
Previous studies have shown that a second organic solvent
is usually necessary to decrease interfacial tension and
provide a flexible interfacial film for formation of nanoemul-
sions (Shafiq et al., 2007; Polychniatou & Tzia, 2014) and act
as co-surfactant in nanoemulsion system (Neslihan Gursoy &
Benita, 2004). Furthermore, co-surfactant can help form
nanoemulsion at lower concentration of surfactant (Keyhanfar
F et al., 2014). Ethanol and PEG400, which were selected as
co-surfactant showed increased transparency when added to
the preparation. Subsequently, optimum excipient concentra-
tions were established by means of ternary diagram studies.
Phase diagrams were constructed to provide information on
nanoemulsion zone and assess relationships between com-
position variation and nanoemulsion formation. Results
indicated that surfactants are not capable to decrease inter-
facial tension enough to form a wide nanoemulsion area.
Thus, addition of a co-surfactant was proposed to aid
nanoemulsion formation. This may be due to increased
fluidity and in turn influencing the curvature of interface and
reduced interfacial tension (Luo et al., 2004).
Our findings also indicated that by increasing the concen-
tration of surfactant or co-surfactant from the Smix ratio of
1:1, nanoemulsion region was reduced in the phase diagram.
In general, increasing the surfactant concentration is expected
to cause more stability and lead to smaller particle size due to
its interfacial activity (Salager, 2002). However, increase of
surfactant over an optimal amount may result in smaller
particles with more Brownian motion and advent of Ostwald
ripening (Izquierdo et al., 2002). On the other hand,
interfacial disruption may occur due to penetration of water
into the oil droplets and thereby ejection of oil droplets into
the aqueous phases (Neslihan Gursoy & Benita, 2004). The
results of phase diagram also showed that the size and
location of nanoemulsion zone were affected by the ratios of
surfactant and surfactant (Azeem et al., 2009).
To study the effect of co-surfactant components on
nanoemulsion area, phase diagrams were constructed again.
In PEG
Etoh
¼ 2
1
, the nanoemulsion region was increased. However,
by increasing the percentage of Etoh, the nanoemulsion
region was reduced. Despite the fact that Etoh as a co-
surfactant can increase fluidity of the interface and form more
stable interfacial film, excess amounts of this molecule may
enter the inner oil phase which increases the droplet size
(Lawrence & Rees, 2000; Xi et al., 2009). It has been shown
that large amounts of surfactants-cosurfactants would cause
Table 1. Mean (±S.D.) percentage transmittance of
formulation with different Smix at 650 nm, 25 C
(n¼ 3).
Component of Smix in formulation %T
T20 + S80 + PEG 55.3 ± 1.5
T20 + S80 + Etoh 66.5 ± 1.8
T20 + S80 + PEG + Etoh 26.6 ± 1.1
T80 + S80 + PEG 62.7 ± 2.5
T80 + S80 + Etoh 81.8 ± 1.6
T80 + S80 + PEG + Etoh 99.0 ± 0.1
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Figure 3. Pseudo-ternary diagram of system with different ratio of surfactant (T80 + S80) to co-surfactant (PEG + Etoh) indicating O/W nanoemulsion
region at different Smix ratios. (A) Smix ratio¼ 1:0; (B) Smix ratio¼ 1:1; (C) Smix ratio¼ 1:2; (D) Smix ratio¼ 1:3; (E) Smix ratio¼ 2:1.
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Figure 4. Pseudo-ternary diagram indicating O/W nanoemulsion region at different co- surfactant ratio. (A) PEG/Etoh¼ 1/1; (B) PEG/Etoh¼ 2/1;
(C) PEG/Etoh¼ 1/2; (D) PEG/Etoh¼ 3/1.
Table 2. Thermodynamic stability test of different formulations selected from phase diagram.
Percentage (w/w) of different components Observation based on thermodynamic stability study
Phase
diagram PEG/Etoh Oil Smix Aqueous H/C Cent. Freez.Tha
A 1:1 10 30 60 ˇ ˇ 
A 1:1 10 45 35 ˇ ˇ ˇ
A 1:1 15 35 50  ˇ 
B 2:1 10 40 50 ˇ ˇ ˇ
B 2:1 10 50 40 ˇ ˇ ˇ
B 2:1 20 50 20  ˇ 
H/C: Heating-cooling cycle; cent: Centrifugation; Freez.Tha: Freeze thaw cycle.
ˇ: Passed; : Failed.
Table 3. Composition, droplet size and polydispersity index of selected nanoemulsion formulations.
Percentage (w/w) different components
in formulation Mean droplet size ± S.D. (nm) PDI ± S.D.
Code Smix* Ratio PEG/Etoh Oil Smix Aqueous Day 1 Month 3 Day 1 Month 3
MF1 1:1 2:1 10 40 50 28.2 ± 3.7 57.6 ± 9.0 0.35 ± 0.03 0.37 ± 0.05
MF2 1:1 2:1 10 50 40 22.8 ± 4.0 35.9 ± 5.5 0.39 ± 0.04 0.26 ± 0.08
MF3 1:1 1:1 10 45 35 35.1 ± 5.2 59.0 ± 7.2 0.36 ± 0.07 0.45 ± 0.10
*Smix indicates mixture of surfactant and co-surfactant in specific volume ratio.
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irritation to the gastrointestinal tract. Also, increase in the
concentration may decrease the thermodynamic activity of the
drug in the vehicle and increase its affinity (Azeem et al.,
2009). Therefore, it is essential to select a formulation with
the lowest amount of Smix (i.e. Oil/Smix¼ 1:5), with
appropriate particle size and PDI for oral delivery of MB.
The results of in vivo experiments have shown that
nanoemulsion formulation was able to enhance bioavailability
of MB significantly compared to the suspension, oil-soluble
and micellar solution. MB has very low aqueous solubility
(0.48–0.5 mg/L). Since the solubility of a drug is the first step
in oral absorption, low solubility can lead to a decreased
bioavailability as well as high intra- and inter-individual
variations in plasma (Stuchlik & Zak, 2001). Utilization of
lipid formulations, such as nanoemulsions can help overcome
this problem (Shen et al., 2011; Gorain et al., 2014; Vatsraj
et al., 2014). Such improvements in bioavailability in drugs,
formulated by lipid- or oil-based formulations may be
explained by different mechanisms: decreased rate of gastric
emptying, increased dissolution rate of the drug, increased
solubility in the intestinal fluid and formation of lipopro-
teins that promote the lymphatic transport of highly lipo-
philic drugs have been suggested in the literature for this
phenomenon (Gershanik & Benita, 2000).
When a drug is administered in the nanoemulsion formu-
lation, oil droplets form mixed micelles with bile salts,
penetrate through the aqueous layer and mucin and reach
systemic blood circulation via portal veins or through the
lymphatic system (Fricker et al., 2010). Previous studies have
shown that hydrophobic drugs which are formulated by oil in
water (o/w) nanoemulsion will be absorbed better than
corresponding lipid solution (Gershanik & Benita, 2000).
Presence of the surfactant in the formulation, in addition to
spreading the drug in the oil droplets, leads to a better
distribution of the drug during the dissolution process in the
lumen (Gao et al., 1998). Furthermore, Tween 80 may inhibit
the efflux system, change the membrane permeability and
increase epithelial permeability of tight junctions and conse-
quently increase drug absorption (Kim et al., 2001). Tween 80
has also shown potential in inhibiting cytochrome P450 3A4
(Bravo Gonzalez et al., 2004) and P-gp (Hugger et al., 2002)
as well as lymphotropic effects (Elsheikh et al., 2012), which
may play a role in bioavailability improvement of MB in
nanoemulsion formulation. Additionally, surfactants could
modify permeability of GI membrane and facilitate drug
entrance to systemic circulation via paracellular pathway
(Chhabra et al., 2011). Nevertheless, it is worth noticing that
stability of the nanoemulsion remains to be a challenge, as
size analysis studies indicated a degree of increase in particle
size which may contribute to phase separation in long-term
storage.
Our results also showed that the bioavailability of micelle
solution was significantly higher than MB suspension. It is
arguable that presence of surfactant and co-surfactant in the
Table 4. Pharmacokinetic parameters upon oral administration of various mebudipine formulations (10 mg/kg) to
rats.
Pharmacokinetic parameters Suspension Oily solution Micellar solution Nanoemulsion
Cmax (ng/ml) 37.8 ± 8.8 56.0 ± 14.5 63.8 ± 9.5 116.8 ± 26.0
a,b,c
Tmax (h) 0.55 ± 0.22 0.83 ± 0.40 0.58 ± 0.20 0.66 ± 0.25
T1/2(h) 3.87 ± 1.41 4.07 ± 0.96 2.41 ± 0.65 3.43 ± 0.90
AUC0!6 (ng h/ml) 79.3 ± 15.3 105.6 ± 18.4 128.9 ± 16.2
d 221.4 ± 32.4a,b,c
AUC0!1 (ng h/ml) 112.7 ± 16.6 147.8 ± 28.1 153.2 ± 19.6 297.3 ± 29.6
a,b,c
Data expressed as mean ± S.D., n¼ 6.
aSignificantly higher (p50.001) compared to MB suspension.
bSignificantly higher (p50.001) compared to MB oily solution.
cSignificantly higher (p50.001) compared to MB micellar solution.
dSignificantly higher (p50.05) compared to MB suspension and oily solution.
Figure 5. Transmission electron micrograph of MB nanoemulsion.
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micelle contributed to increased intestinal permeation of MB
by P-gp inhibition and paracellular route (Choi et al., 2015).
Conclusion
The study indicated that a nanoemulsion system may be able
to improve oral bioavailability of a poorly water soluble drug
in vivo. Pharmacokinetic study of the optimized formulation
in rat models indicated significantly higher relative bioavail-
ability in nanoemulsion compared with suspension, oily
solution and micellar solution. It was concluded that the use
of nanoemulsion may reduce the dose needed for clinical
studies.
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